[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhongda Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":594},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,41,64,89,113,138,164,187,212,230,252,277,299,318,338,356,377,403,431,457,480,503,528,550,573],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100637057","assessment-of-cfdna-sting-axis-as-a-potential-pathological-marker-in-atopic-dermatitis-100637057",false,"NCT07573735","Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis","An Observational Study on the Correlation Between Circulating Cell-free DNA and Skin Macrophage STING Pathway Activation in Patients With Atopic Dermatitis","Inclusion Criteria:\n\n* Age 18 years or older\n* Confirmed diagnosis of Atopic Dermatitis\n\nExclusion Criteria:\n\n* Use of systemic immunosuppressants, systemic corticosteroids, or biological agents within 4 weeks prior to enrollment\n* Use of topical treatments within 2 weeks prior to enrollment",true,"ALL","18 Years",{"count":21,"type":22},80,"ESTIMATED","1 Day","OBSERVATIONAL","Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage. While researchers know that the immune system is overactive in AD, it is difficult to measure the exact level of \"damage\" or \"inflammation\" happening deep within the skin using only a physical exam.\n\nThe Purpose of This Study This study investigates a specific \"danger signal\" called circulating cell-free DNA (cfDNA). When skin cells are damaged or die due to inflammation, they release tiny fragments of DNA into the bloodstream. The investigators believe these fragments might act as a trigger for the immune system, worsening the disease.\n\nWhat the Study Involves Researchers will collect blood samples and small skin biopsies from patients with AD and healthy volunteers.\n\nThe study aims to: Compare the levels of cfDNA in the blood of AD patients versus healthy individuals. Determine if higher levels of cfDNA correlate with more severe skin symptoms (measured by scores like SCORAD and EASI). Examine how immune cells in the skin (macrophages) respond to these DNA fragments through a specific biological switch called the STING pathway.\n\nPotential Impact By understanding this \"damage-signal\" loop, this research may lead to new ways for doctors to monitor AD severity through simple blood tests and could identify new targets for future anti-inflammatory treatments.",[27],"Atopic Dermatitis (Eczema)","RECRUITING","2026-06-09",{"date":31,"type":32},"2026-06-11","ACTUAL",{"date":34,"type":32},"2026-02-01",{"date":36,"type":22},"2026-07-31",{"name":38,"class":39},"Zhongda Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":48,"enrollmentInfo":49,"targetDuration":51,"studyType":24,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100619980","a-multicenter-prospective-study-on-the-performance-of-spectral-ct-for-evaluating-treatment-response-after-tace-in-hepatocellular-carcinoma-100619980","NCT07351669","A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma","The Performance of Spectral CT in Evaluating Treatment Response After Transarterial Chemoembolization for Hepatocellular Carcinoma: The SpecTRAIL Study","Inclusion Criteria:\n\n1. age 18-75 years;\n2. diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria;\n3. Barcelona Clinic Liver Cancer (BCLC) stage A or B;\n4. prior treatment with TACE;\n5. undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE;\n6. undergoing either liver resection within 1 week after contrast-enhanced spectral CT (surgical cohort) or undergoing hepatic digital subtraction angiography (DSA) or contrast-enhanced MRI within 1 week after contrast-enhanced spectral CT (non-surgical cohort);\n7. informed consent.\n\nExclusion Criteria:\n\n1. contraindications to contrast-enhanced CT or MRI;\n2. presence of extrahepatic malignancy;\n3. poor image quality or incomplete clinical data;\n4. lack of regular CT or MRI follow-up in non-surgical cohort;\n5. withdrawal from the study.","75 Years",{"count":50,"type":22},121,"1 Year","By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment response following TACE for hepatocellular carcinoma.",[54,55,56],"HCC - Hepatocellular Carcinoma","TACE(Transcatheter Arterial Chemoembolization)","CT",{"date":58,"type":32},"2026-06-10",{"date":60,"type":32},"2026-01-20",{"date":62,"type":22},"2028-06-30",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100639657","the-impact-of-blood-pressure-variability-during-the-induction-and-surgical-periods-on-postoperative-acute-kidney-injury-100639657","NCT07602465","The Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury","Inclusion Criteria:\n\n* Undergoing non-cardiac surgery；\n* Adult；\n\nExclusion Criteria:\n\n* Undergoing urological surgeries that partially directly affect kidney function (including relief of urinary tract obstruction, nephrectomy, or kidney transplantation);\n* Surgery duration less than 60 minutes;\n* Weight \\\u003C 30 kg or BMI \\> 35 kg\u002Fm2;\n* Patients who underwent reoperation within 7 days after surgery;\n* Surgeries not performed under general anesthesia;\n* ASA \\> IV;\n* No serum creatinine measurement available within 6 months before surgery (baseline value) or within 7 days after surgery;\n* Preexisting renal dysfunction or a diagnosis of chronic kidney disease before surgery (creatinine \\> 443 μmol\u002FL);\n* No invasive blood pressure monitoring during the anesthesia induction period, or missing more than 25% of intraoperative invasive blood pressure data collection.",{"count":71,"type":22},5000,"The goal of this multicenter retrospective cohort study aimed to explore the effect of BPV during anesthesia induction and surgery on the occurrence of postoperative AKI in non-cardiac surgery patients.",[74],"Acute Kidney Injury (AKI)",[76,77,78,79],"Acute kidney injury","Blood pressure variability","Anesthesia induction period","Non-cardiac surgery","NOT_YET_RECRUITING","2026-05-21",{"date":83,"type":32},"2026-05-27",{"date":85,"type":22},"2026-06-01",{"date":87,"type":22},"2026-12-01",{"name":38,"class":39},{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":95,"minAge":19,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100632670","early-phase-1-safety-and-efficacy-of-docetaxel-darolutamide-and-homoharringtonine-combined-with-androgen-deprivation-therapy-in-neoadjuvant-treatment-of-high-risk-prostate-cancer-a-multicenter-prospective-single-arm-clinical-study-100632670","NCT07516704","Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study","Inclusion Criteria:\n\n* ① Age ≥ 18 years and ≤ 85 years;\n\n  * Histologically or cytologically confirmed prostate cancer;\n\n    * High-risk prostate cancer: meeting at least one of the following criteria: clinical stage T3-T4, or Gleason score 8-10, or PSA \\> 20 ng\u002FmL, or presence of distant metastasis (clinical stage M1); ④ ECOG (Eastern Cooperative Oncology Group) performance status score of 0-1; ⑤ All patients voluntarily sign informed consent and are able to adhere to treatment and follow-up\n\nExclusion Criteria:\n\n* ① Any prior or ongoing treatment for prostate cancer, including radiotherapy, chemotherapy, ADT, etc.;\n\n  * Previous prostatectomy; ③ Any other serious underlying medical, psychiatric, or psychological conditions that, in the investigator's judgment, may affect treatment;\n\n    * Allergy to any of the study drugs; ⑤ Refusal to undergo radical prostatectomy; ⑥ Deemed unsuitable for participation in this clinical trial by the investigator's judgment.","MALE","85 Years",{"count":98,"type":22},94,"INTERVENTIONAL",[101],"EARLY_PHASE1","Previous study findings suggest that the efficacy limitations of the neoadjuvant treatment regimen combining docetaxel with androgen deprivation therapy are associated with protein synthesis. Homoharringtonine (HHT) is currently the only small-molecule translation elongation inhibitor approved by the U.S. Food and Drug Administration (FDA). Building on this foundation, we plan to conduct a prospective interventional study aimed at validating whether the intensified quadruple regimen, formed by adding darolutamide and homoharringtonine (HHT) to the standard regimen, can further significantly enhance the depth of pathological response and improve patient outcomes through multi-mechanism synergy.",[104],"Prostate Cancer","2026-03-31",{"date":107,"type":32},"2026-04-08",{"date":109,"type":22},"2026-04-01",{"date":111,"type":22},"2027-12-12",{"name":38,"class":39},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100631749","trunk-inclination-positive-end-expiratory-pressure-and-lung-recruitability-100631749","NCT07504731","Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability","Impact of Trunk Inclination on Lung Mechanics According to PEEP and Reruitability","Inclusion Criteria:\n\n* Intubated moderate and severe ARDS according to the Berlin definition (PaO2\u002FFiO2 ratio \\\u003C= 200 mmHg)\n* Under continuous sedation with or without paralysis\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Bronchopleural fistula\n* Pure COPD exacerbation\n* Contraindication to EIT monitoring (e.g. burns, pacemaker, thoracic wounds limiting electrode belt placement)\n* Hemodynamic instability (Systolic BP \\\u003C 75 mmHg or MAP \\\u003C 60 mmHg despite vasopressors and\u002For heart rate \\\u003C 55 bpm)\n* Contraindications to mobilization (e.g., intracranial hypertension, spinal cord injury)\n* Intra-abdominal hypotension (IAP≥12mmHg)\n* Pregnancy\n* Attending physician deems the transient application of high airway pressures to be unsafe",{"count":121,"type":22},40,"This multicenter, physiological, observational study hypothesizes that in moderate to severe ARDS, trunk inclination unloads the chest wall, but its impact on lung mechanics depends on PEEP levels and lung recruitability.",[124],"Acute Respiratory Distress Syndrome (ARDS)",[126,127,128,129],"trunk inclination","lung mechanics","positive end-expiratory pressure","lung recruitability","2026-03-25",{"date":109,"type":32},{"date":133,"type":32},"2026-03-20",{"date":135,"type":22},"2027-04-30",{"name":38,"class":39},3,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":48,"enrollmentInfo":146,"targetDuration":4,"studyType":99,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":40},"100630012","therapeutic-effect-of-electroacupuncture-at-zusanli-st-36-on-diabetic-foot-wounds-100630012","NCT07482137","Therapeutic Effect of Electroacupuncture at Zusanli (ST-36) on Diabetic Foot Wounds","Clinical Observation and Mechanism Study on the Therapeutic Effect of Electroacupuncture at Zusanli (ST-36) in Promoting Diabetic Foot Wound Healing Through Mediating Macrophage Polarization","EA for DFU","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for diabetic foot ulcers;\n2. Meet the criteria for Traditional Chinese Medicine syndrome differentiation, classified as blood stasis obstructing the collateral pattern;\n3. Wagner Grade 1-3, with ulcer area ranging from 2 cm² to 30 cm²;\n4. Male or female, aged between 18 and 75 years;\n5. Provide signed informed consent, voluntarily participate in this study, and demonstrate good compliance.\n\nExclusion Criteria:\n\n1. Complicated with severe diseases of the brain, liver, heart, lungs, or kidneys;\n2. Pregnant women or women planning to become pregnant;\n3. Glycosylated hemoglobin (HbA1c) level ≥ 9%;\n4. Complicated with psychiatric disorders;\n5. Complicated with genetic or infectious diseases, malignant tumors, or other severe conditions associated with a short life expectancy;\n6. Concurrent participation in other clinical trials or participation within 4 weeks prior to randomization.",{"count":147,"type":22},76,[149],"NA","The goal of this clinical trial is to learn if electroacupuncture at the Zusanli (ST-36) can assist in the treatment of diabetic foot ulcers. The main question it aims to answer is: Can electroacupuncture at the Zusanli (ST-36) promote wound healing in patients with diabetic foot ulcers?\n\nResearchers will compare outcomes between participants receiving electroacupuncture plus standard treatment and those receiving standard treatment alone to assess the effect of Zusanli (ST36) stimulation on wound healing in patients with diabetic foot ulcers.\n\nParticipants will:\n\nReceive standard diabetes treatment (including diabetes education, dietary control, insulin combined with oral hypoglycemic agents to manage blood glucose, and effective antibiotics to control infection. For patients with foot ulcers, the wound will be cleaned with saline; abscesses will be drained if present; daily dressing changes.) Participants in the electroacupuncture group will receive electroacupuncture at Zusanli(ST-36) every day; 6 sessions constitute one treatment course, for a total of 4 courses.\n\nVisit the hospital for examinations before treatment and after each treatment course to measure the ankle-brachial index (ABI), assess diabetic foot Wagner grade, and evaluate hemodynamic parameters.",[152],"Diabetes Foot Care",[154,155],"Diabetic Foot Ulcers","Electroacupuncture","2026-03-15",{"date":158,"type":32},"2026-03-19",{"date":160,"type":32},"2025-07-15",{"date":162,"type":22},"2027-12-31",{"name":38,"class":39},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":171,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":40},"100549172","personalized-ventilation-based-on-ventilation-perfusion-mismatch-and-lung-recruitability-100549172","NCT06430554","Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability","Personalized Ventilatory Strategy Based on Ventilation-perfusion Mismatch and Lung Recruitability in Moderate-to-severe ARDS Patients","Inclusion Criteria:\n\n1. age ≥18 years\n2. Moderate-to-severe ARDS as per the 2023 ESICM definition\n3. Undergoing invasive mechanical ventilation\n4. Planned prone position based on the attending physicians' decisions\n5. Signed informed consent\n\nExclusion Criteria:\n\n1. age ≥85 years\n2. Pregnancy\n3. Severe hemodynamic instability (\\> 30% increase in vasopressors in the last 6 hours or norepinephrine \\> 0.5 µg\u002Fkg\u002Fmin)\n4. Clinically suspected elevated intracranial pressure (\\>18 mm Hg)\n5. Bronchopleural fistula\n6. Contraindication to EIT monitoring (e.g. burns, pacemaker, thoracic wounds limiting electrode belt placement)\n7. Severe hypernatremia (\\>170mmol\u002FL)\n8. Re-admission of patients already enrolled in this study, or patients who are participating in other studies",{"count":121,"type":22},"This observational study will explore the effects of PEEP and position on regional lung ventilation-perfusion mismatch by electrical impedance tomography (EIT) in moderate-to-severe ARDS patients with different lung recruitability.",[174,175,176],"Respiratory Distress Syndrome","Positive-Pressure Respiration","Mechanical Ventilation",[178],"Acute respiratory distress syndrome;Positive end expiratory pressure; Prone Position; Ventilation\u002Fperfusion matching.","2026-01-29",{"date":181,"type":32},"2026-02-03",{"date":183,"type":32},"2024-06-08",{"date":185,"type":22},"2026-06-30",{"name":38,"class":39},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":193,"enrollmentInfo":194,"targetDuration":196,"studyType":24,"phases":4,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100618927","a-study-on-the-safety-and-effectiveness-of-endoscopic-intracavitary-submucosal-dissection-for-gastric-extracavitary-type-submucosal-tumors-100618927","NCT07337980","A Study on the Safety and Effectiveness of Endoscopic Intracavitary Submucosal Dissection for Gastric Extracavitary-Type Submucosal Tumors","Inclusion Criteria:\n\n* (1) CT scan showed extramural protrusion of the stomach (2) ultrasonic endoscopy revealed submucosal tumors with extra-gastric growth; (3) patients received ESD\u002FEFTR or surgical treatment\n\nExclusion Criteria:\n\n* (1) patients had malignant tumors in the stomach or had undergone stomach surgery (2) follow-up records were incomplete.","80 Years",{"count":195,"type":22},20,"12 Months","The aim of this study is to explore the safety and efficacy of endoscopic surgery in the treatment of extraluminal growing stromal tumors",[199,200],"Interstitialoma","Endoscopic Surgery",[202,203],"endoscopic surgery","interstitialoma","2026-01-03",{"date":206,"type":32},"2026-01-13",{"date":208,"type":22},"2026-01-01",{"date":210,"type":22},"2026-12-31",{"name":38,"class":39},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":95,"minAge":19,"maxAge":96,"enrollmentInfo":218,"targetDuration":4,"studyType":99,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":40},"100616922","propranolol-combined-with-novel-endocrine-therapy-and-androgen-deprivation-therapy-adt-for-neoadjuvant-treatment-in-high-risk-prostate-cancer-patients-a-multicenter-single-arm-clinical-study-100616922","NCT07311915","Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 85 years;\n\n  * High-risk prostate cancer patients. High-risk prostate cancer is defined as: organ-confined high-risk\u002Fvery high-risk prostate cancer and locally advanced prostate cancer. High-risk\u002Fvery high-risk is specifically defined as PSA \\> 20 ng\u002FmL, biopsy Gleason score ≥ 8, or clinical T stage cT2c or higher, meeting at least one of these three criteria, and without distant metastasis. Local progression typically refers to pelvic lymph node metastasis only; ③ Patients diagnosed with mild to moderate primary hypertension according to the Chinese Hypertension Prevention and Treatment Guidelines (2024 Revised Edition). Hypertension is defined as:\n\n    * Office blood pressure ≥140\u002F90 mmHg without antihypertensive medication; or home blood pressure ≥135\u002F85 mmHg; or 24-hour ambulatory blood pressure ≥130\u002F80 mmHg, with daytime blood pressure ≥135\u002F85 mmHg and nighttime blood pressure ≥120\u002F70 mmHg. Specifically: - Systolic blood pressure 140-159 mmHg and\u002For diastolic blood pressure 90-99 mmHg constitutes mild hypertension; - Systolic blood pressure 160-179 mmHg and\u002For diastolic blood pressure 100-109 mmHg constitutes moderate hypertension.\n\n      * For patient screening, office blood pressure must meet any one of the following criteria:\n\n        1. Primary hypertension patients who have not used any antihypertensive medication for at least 4 weeks prior to screening, with an average seated office blood pressure (mean of 3 measurements) of 150 mmHg ≤ SBP \\\u003C 180 mmHg and DBP \\\u003C 110 mmHg;\n        2. Patients with primary hypertension who have been on stable doses of 1-2 antihypertensive agents (including monotherapy, dual therapy, or fixed-dose combinations) for at least 4 weeks prior to screening, and who are deemed clinically suitable for switching to propranolol or nifedipine, with an average seated office blood pressure of 140 mmHg ≤ SBP \\\u003C 180 mmHg and DBP \\\u003C 110 mmHg; ⑤ ECOG (Eastern Cooperative Oncology Group) performance status of 0-1;\n\n           ⑥ All patients voluntarily sign informed consent and are able to adhere to treatment and follow-up;\n\n           ⑦ Prostate cancer biopsy specimens and surgically resected tissue are available for subsequent analysis, with sufficient tumor cell content in the pathological specimens;\n\n           Exclusion Criteria:\n* Any prior or ongoing PCa treatment, including radiotherapy, chemotherapy, ADT, etc.;\n\n  * Individuals contraindicated for propranolol. Specifically including: 1) Patients with asthma and allergic rhinitis; 2) Patients with cardiovascular disease: sinus bradycardia, severe atrioventricular block, cardiogenic shock; 3) Patients with cardiac insufficiency; 4) Patients with hepatic impairment; 5) Patients with hypothyroidism; ③ Patients who have recently (within 3 months) taken beta-blocker medications (e.g., carvedilol, metoprolol);\n\n    * Patients with known allergies to any medication used; ⑤ Patients on long-term antiarrhythmic drugs (e.g., amiodarone, sotalol, digoxin, verapamil, flecainide); ⑥ Patients deemed unsuitable for this clinical study by the investigator's judgment;",{"count":219,"type":22},30,[149],"Propranolol, a non-selective adrenergic beta-receptor blocker, is conventionally used to treat arrhythmias. However, recent studies have demonstrated its therapeutic efficacy in breast cancer, prostate cancer, neonatal hemangioma, and neonatal facial rhabdomyoma. Given the significant potential of neoadjuvant therapy in prostate cancer, we designed a multicenter, single-arm clinical study. This trial evaluates neoadjuvant propranolol combined with novel endocrine therapy and androgen deprivation therapy (ADT) in high-risk prostate cancer patients prior to radical prostatectomy, aiming to achieve superior curative outcomes.",[104],{"date":224,"type":32},"2026-01-06",{"date":226,"type":22},"2026-01-15",{"date":228,"type":22},"2028-09-30",{"name":38,"class":39},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":40},"100613608","effect-of-roxadustat-on-heart-failure-patients-with-anaemia-and-moderate-to-severe-chronic-kidney-disease-100613608","NCT07268807","Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease","Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease: A Single-Centre Retrospective Study","Inclusion Criteria:\n\n* aged 18-85 years, regardless of gender;\n* fulfilled the diagnostic criteria for heart failure and chronic kidney disease;\n* haemoglobin level \\\u003C130 g\u002FL for men or \\\u003C120 g\u002FL for women at baseline;\n* had regularly received Roxadustat for over one year;\n* possessed complete clinical data, including information from pre-specified time points.\n\nExclusion Criteria:\n\n* comorbid myelodysplastic syndromes, multiple myeloma, hereditary hematologic diseases (e.g., thalassemia, sickle cell anaemia, pure red cell aplasia), hemosiderosis, hemochromatosis, or other disorders confirmed to cause anaemia due to erythrocyte destruction and\u002For abnormal hematopoietic function;\n* haemoglobin level ≤45 g\u002FL on two or more blood tests, a history of major bleeding within one year, or a history of anaemia corrected by blood transfusion;\n* bilateral nephrectomy, kidney transplantation within ≤6 months, or congenital kidney diseases (e.g., polycystic kidney disease);\n* hypertrophic obstructive cardiomyopathy or congenital heart disease with right-to-left shunt;\n* comorbid malignancy with an investigator-assessed life expectancy of less than 12 months;\n* pregnancy or lactation;\n* known allergy to the study drug (active ingredient or excipients);\n* participation in a drug clinical trial within one year.",{"count":238,"type":22},200,"Previous clinical observations of potential benefit from Roxadustat in this complex patient population prompted this investigation Therefore, the investigators designed this retrospective, observational study to thoroughly investigate the effects of Roxadustat on heart failure treatment and ventricular remodelling in this specific patient population, aiming to provide new insights for patients management.",[241,242,243],"Heart Failure","CKD","Anemia","2025-12-03",{"date":246,"type":32},"2025-12-08",{"date":248,"type":22},"2025-12-01",{"date":250,"type":22},"2026-09-01",{"name":38,"class":39},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":99,"phases":261,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":40},"100594820","sigh-ventilation-in-cardiac-surgery-100594820","NCT07024420","Sigh Ventilation in Cardiac Surgery","Effect of Sigh Ventilation on Postoperative Pulmonary Complications in Cardiac Surgery: A Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years of age or older;\n* Elective cardiac surgery with cardiopulmonary bypass, aortic clamp and cardioplegia;\n* Written informed consent is obtained from patients and\u002For their legal representatives.\n\nExclusion Criteria:\n\n* Emergence surgery;\n* Left ventricular assist device implantation;\n* Planned thoracotomy with one lung ventilation;\n* Undergo concurrent surgical procedures outside cardiology;\n* Neuromuscular illness;\n* Mechanical ventilation within the last 2 weeks before surgery, include CPAP and NIV;\n* Preoperative shock;\n* Preoperative Hypoxemia (PaO2\\\u003C60mmHg OR SpO2\\\u003C90% on ambient air);\n* Preoperative left ventricular ejection fraction \\\u003C 40%;\n* Systolic pulmonary artery pressure \\> 50 mmHg.",{"count":260,"type":22},686,[149],"The purpose of this trial is to investigate whether sigh ventilation strategy, combining sigh breaths, low tidal volume, and moderate PEEP levels, protects against major pulmonary complications within the first 7 postoperative days after cardiac surgery, as compared with conventional ventilation strategy with low tidal volume, and moderate PEEP levels.",[264,265],"Postoperative Pulmonary Complications (PPCs)","Cardiac Surgery in Adult Patient",[267,268,269],"Sigh Ventilation","Cardiac Surgery","Postoperative Pulmonary Complications","2025-11-14",{"date":272,"type":32},"2025-11-18",{"date":274,"type":32},"2025-10-09",{"date":162,"type":22},{"name":38,"class":39},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":48,"enrollmentInfo":284,"targetDuration":4,"studyType":99,"phases":286,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":40},"100607340","phase-1-edn-combined-with-tacehaic-and-second-line-immune-targeted-treatment-versus-tacehaic-alone-in-locally-advanced-hcc-with-portal-vein-tumor-thrombosis-after-first-line-therapy-failure-a-prospective-multicenter-randomized-controlled-trial-100607340","NCT07187284","EDN Combined With TACE\u002FHAIC and Second-Line Immune-Targeted Treatment Versus TACE\u002FHAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial","Evaluating Endervascular Denervation (EDN) Combined With Transarterial Intervention (TACE\u002FHAIC) and Second-Line Immune-Targeted Therapy in Locally Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Tumor Thrombosis After Progression on First-Line Systemic Therapy: A Prospective, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive), regardless of gender.\n2. Diagnosis of CNLC Stage IIIa HCC with portal vein tumor thrombus (vp type 1-3) confirmed by histopathology, cytology, or imaging.\n3. Progression of disease after first-line systemic therapy.\n4. At least one measurable lesion according to RECIST 1.1 criteria.\n5. Child-Pugh class A or B.\n6. ECOG performance status of 0 to 2.\n7. Scheduled to undergo TACE or HAIC treatment.\n8. Adequate hematological, hepatic, and renal function within 14 days prior to study initiation, defined as:\n\nWhite blood cell count ≥2.0×10⁹\u002FL AND neutrophil count ≥1.0×10⁹\u002FL. Platelet count ≥60×10⁹\u002FL. Hemoglobin concentration ≥90 g\u002FL. Total bilirubin ≤2.0 × upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN. Albumin ≥2.8 g\u002FdL. International normalized ratio (INR) ≤1.6. Creatinine ≤1.5 × ULN AND calculated creatinine clearance ≥30 mL\u002Fmin.\n\nExclusion Criteria:\n\n1. Preoperative abdominal CT or MR enhanced scan suggests celiac trunk anatomy is unsuitable for EDN procedure.\n2. History of orthostatic hypotension.\n3. Diffuse liver tumors or extensive extrahepatic metastases with an expected survival of \\\u003C3 months.\n4. Cachexia or multi-organ failure.\n5. Severe hepatic dysfunction (Child-Pugh class C).\n6. Uncorrectable coagulation dysfunction.\n7. Presence of severe concurrent infection.\n8. Accompanied by Vp4 type portal vein tumor thrombus.\n9. Abnormal blood supply to the target lesion that precludes transarterial interventional therapy.\n10. History of bilioenteric anastomosis within the past year.\n11. Severe allergy to known contrast agents or embolization materials.\n12. Pregnant or lactating women, or individuals with childbearing potential planning pregnancy during the trial period.\n13. Clinically significant (e.g., active) cardiovascular disease, including:\n\n    Unstable angina within ≤6 months prior to randomization. New York Heart Association (NYHA) class ≥II congestive heart failure. Poorly controlled arrhythmia despite medication (patients with controlled atrial fibrillation are eligible), or any clinically significant abnormality found on resting ECG.\n\n    ≥Grade 3 peripheral vascular disease (e.g., symptomatic and interfering with activities of daily living, requiring intervention).\n\n    Transient ischemic attack or subarachnoid hemorrhage within 6 months prior to randomization, or participation in other drug or device clinical trials within 3 months.\n14. History of other malignancies within the past 5 years or concurrent other malignancies.\n15. Any other condition deemed by the investigator as unsuitable for participation in this study.",{"count":285,"type":22},62,[287,288],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization\u002F hepatic arterial infusion chemotherapy (TACE\u002FHAIC) plus second-line immune-targeted therapy in patients with locally advanced hepatocellular carcinoma (HCC) who have progressed after first-line systemic therapy and present with portal vein tumor thrombus (PVTT).\n\nThe main questions this study aims to answer are:\n\nDoes the addition of EDN to standard TACE\u002FHAIC and immune-targeted therapy improve intrahepatic progression-free survival (hPFS) based on RECIST 1.1 criteria? What is the safety profile of the combined treatment, including device-related adverse events? Researchers will compare the experimental group (EDN + TACE\u002FHAIC + immune-targeted therapy) with the control group (TACE\u002FHAIC + immune-targeted therapy alone) in a 1:1 randomized design. A total of 62 participants will be enrolled across 8 centers, with an expected enrollment period of 12 months and a 12-month follow-up period.\n\nParticipants will:\n\nUndergo screening assessments including imaging (CT\u002FMRI), blood tests, and ECG within specified time windows.\n\nReceive assigned interventions (EDN procedure or control) during the baseline visit (Day 0).\n\nAttend follow-up visits at 1 month (±7 days), 3 months (±14 days), 6 months (±30 days), 9 months (±30 days), and 12 months (±30 days) for repeated imaging, laboratory tests, and safety evaluations.\n\nHave their tumor response, survival outcomes, and adverse events monitored throughout the study.",[54],"2025-09-19",{"date":293,"type":32},"2025-09-22",{"date":295,"type":22},"2025-09-30",{"date":297,"type":22},"2027-09-30",{"name":38,"class":39},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":99,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100601349","development-and-prospective-validation-of-a-heterogeneous-treatment-effect-based-decision-model-for-transarterial-chemoembolization-combined-with-or-without-atezolizumab-plus-bevacizumab-in-unresectable-hepatocellular-carcinoma-100601349","NCT07109336","Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n* • Aged≥18 years\n\n  * Initiated first-line Atezo+Bev.\n  * Eligible for TACE treatment or received at least one TACE within ±2 months of Atezo+Bev initiation (before Atezo+Bev start, anytime during Atezo+Bev therapy, or after Atezo+Bev discontinuation).\n  * Clinically or pathologically diagnosed uHCC before or at the initiation of Atezo\u002FBev.The evidence of being diagnosed as \"unresectable\" may include but is not limited to below:\n\n\"Unresectable\" or \"advanced\" directly documented in the medical records History of extrahepatic metastasis as evidenced clinically or by radiology, histology or cytology OR China Liver Cancer (CNLC) Stage IIIb\n\n* At least one visit record after the initiation of Atezo+Bev\n* No prior systemic therapy for HCC, especially immunotherapy\n* No prior locoregional therapy to the target lesion(s)\n* At least one measurable untreated lesion\n* ECOG Performance Status of 0-2\n\nExclusion Criteria:\n\n* • Evidence of extrahepatic spread (EHS)\n\n  * Participating in interventional clinical trials.\n  * Being a candidate for curative treatments\n  * Any condition representing a contraindication to TACE as determined by the investigators\n  * Active or history of autoimmune disease or immune deficiency\n  * Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or high risk for bleeding\n  * A prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment\n  * Evidence of bleeding diathesis or significant coagulopathy\n  * Missing critical baseline or outcome data",{"count":306,"type":22},790,[149],"Unresectable hepatocellular carcinoma (uHCC) constitutes a significant health burden in the Asia-Pacific (APAC) region, particularly in China, where it is frequently associated with hepatitis B virus (HBV) infection and diagnosed at advanced stages.\n\nTransarterial chemoembolization (TACE) remains the standard treatment for intermediate-stage hepatocellular carcinoma (HCC), though its effectiveness diminishes in unresectable HCC (uHCC) with intermediate-to-high tumor burden. The IMbrave150 trial established atezolizumab plus bevacizumab (Atezo+Bev) as a superior alternative to sorafenib, demonstrating significant survival advantages in uHCC. Given the marked heterogeneity of intermediate-stage HCC, TACE may not benefit all patients equally. The TALENTACE study investigated on-demand TACE combined with Atezo+Bev versus TACE alone in treatment-naïve uHCC patients with intermediate-to-high tumor burden across China and Japan. Results revealed a statistically significant and clinically meaningful improvement in the primary endpoint, TACE- progression-free survival (PFS), though overall survival (OS) remained immature at the time of analysis.\n\nThis situation establishes a critical and unmet need for randomized controlled trials (RCTs) combined with extensive real-world evidence (RWE) to facilitate the assessment of individualized treatment heterogeneity and provide precise treatment recommendations in China and select Asia-Pacific regions.",[54],"2025-07-30",{"date":312,"type":32},"2025-08-07",{"date":314,"type":22},"2025-08-01",{"date":316,"type":22},"2027-01-01",{"name":38,"class":39},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":337,"locationsCount":4},"100597759","a-multicentre-clinical-study-100597759","NCT07062666","A Multicentre Clinical Study","A Multicentre Clinical Study of Near Infrared Functional Brain Imaging Combined With Eye Tracking Technique for the Auxiliary Diagnosis and Treatment Effect Prediction of Depression","Inclusion Criteria:\n\n* Aged 18-60 years old; ② Right-handed; ③ Meet the DSM-5 diagnostic criteria for depression; ④ The current course of disease (last onset) is at least 2 weeks; ⑤HAMD-17 score ≥17 points; ⑥ No electroconvulsive therapy was received in the first six months.\n\nExclusion Criteria:\n\n* A combination of another mental illness; A history of alcohol\u002Fdrug dependence or smoking \\> 10 cigarettes\u002Fday; ③ Serious physical diseases of the heart, liver, kidney, brain and hematopoietic system, central nervous system infection, head injury, epilepsy, multiple sclerosis, toxic metabolic diseases, Parkinson's disease or intracranial tumors; ④ Family history of hereditary diseases; ⑤Endocrine system diseases such as diabetes, hyperthyroidism or hypothyroidism; ⑥ Pregnant, lactating women or photosensitivities.","60 Years",{"count":327,"type":22},2250,"This study intends to conduct a multi-center, large-sample clinical trial, aiming at using multi-channel near-infrared spectroscopy to detect the characteristics of brain Oxy-Hb changes over time during cognitive activation in patients with depression before treatment and in the gender - and age-matched control group, and using eye tracking technology to detect the eye movement characteristics of patients with depression before treatment and in the gender - and age-matched control group. The sensitivity and specificity of fNIRS spectrum and eye movement index in objective diagnosis of patients with depressive disorder were calculated, and according to the HAMD reduction rate, depression patients after 2 weeks of treatment were divided into remission group and non-remission group. fNIRS imaging and eye movement indexes in depression group and normal control group were compared, fNIRS imaging and eye movement indexes in depression remission group before and after treatment, fNIRS imaging and eye movement indexes in depression remission group and non-remission group were compared at baseline to verify the biomarkers of fNIRS spectrum and eye movement indexes in predicting antidepressant efficacy. Finally, it provides reliable scientific evidence for the important role of fNIRS imaging and eye tracking technology in the diagnosis and treatment of depression.",[330],"the Objective Diagnosis of Depression","2025-07-11",{"date":333,"type":32},"2025-07-14",{"date":310,"type":22},{"date":336,"type":22},"2025-08-31",{"name":38,"class":39},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100598001","team-familiarity-and-perioperative-outcomes-in-non-cardiac-surgery-100598001","NCT07065812","Team Familiarity and Perioperative Outcomes in Non-Cardiac Surgery","The Impact of Team Familiarity on Surgical Outcomes and Patient Safety in Non-Cardiac Surgery","Inclusion Criteria:\n\n* All elective surgeries for adults (age ≥18 years)\n\nExclusion Criteria:\n\n* Surgeries in which patient demographics (age, gender), ASA grade, procedure details, and positional data were unattainable\n* Cardiac surgical procedures (with a fixed surgical team)\n* Operations under non-intubated general anesthesia or intravenous anesthesia (primarily diagnostic procedures not requiring close multidisciplinary collaboration)\n* Surgical cases with missing data on pre-anesthesia preparation time, anesthesia induction time, and surgical procedure duration\n* Surgical cases with missing data on team members' years of experience and gender information.\n* Surgical cases with missing data on intra- and post-operative major complications and other safety-related outcome measures",{"count":346,"type":22},100000,"The goal of this retrospective observational study is to quantify the impact of team collaboration on work efficiency in operating room and patient safety outcomes in non-cardiac surgical teams. The main purpose is to answer:\n\nHow does team collaboration affect work efficiency in operating room and patient safety outcomes during\u002Fafter surgery? The data will be obtained from the Hospital Electronic Medical Record Information System, participants already finished all the planned surgeries.",[349],"Operating Room Efficiency","2025-07-03",{"date":160,"type":32},{"date":160,"type":22},{"date":354,"type":22},"2026-05-30",{"name":38,"class":39},{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":99,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":40},"100593926","efficacy-analysis-of-saccharomyces-boulardii-combined-with-minocycline-in-treatment-nave-patients-with-helicobacter-pylori-infection-100593926","NCT07012785","Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection","Inclusion Criteria:\n\n1. Aged 18-70 years, regardless of gender;\n2. Positive 13C\u002F14C urea breath test result;\n3. No previous history of H. pylori eradication treatment;\n4. Agreement to participate in this study and signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of ≥ 1 instance of failed H. pylori eradication;\n2. Use of antibiotics (including antibacterial traditional Chinese medicines), nonsteroidal anti-inflammatory drugs (NSAIDS), bismuth agents, H2 receptor antagonists (H2RAs), proton-pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CAB) within 4 weeks before treatment;\n3. Plans to conceive, pregnancy, or breastfeeding;\n4. Severe liver, kidney, or cardiovascular diseases; malignancies; and alcoholism;\n5. Allergies to the drugs used in this study or a history of penicillin allergy;\n6. The inability to correctly express one's symptoms and wishes, such as inability due to mental illness or severe neurosis.","70 Years",{"count":364,"type":22},208,[149],"To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection",[368],"H. Pylori Infection","2025-06-02",{"date":371,"type":32},"2025-06-10",{"date":373,"type":22},"2025-06",{"date":375,"type":22},"2025-12",{"name":38,"class":39},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":99,"phases":386,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":40},"100586002","sirt-versus-ctace-for-unresectable-hcc-chance2506-100586002","NCT06909708","SIRT Versus cTACE for Unresectable HCC (CHANCE2506)","SIRT (Yttrium-90 Carbon Microspheres) Versus cTACE for Unresectable Hepatocellular Carcinoma: A Multicenter, Prospective, Open-label, Phase 3 Trial (CHANCE2506)","Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group performance status ≤ 1;\n2. Expected survival time ≥ 3 months;\n3. Confirmed hepatocellular carcinoma based on CNLC guidelines;\n4. Without extrahepatic metastases, unresectable or refuse surgical resection;\n5. At least one well defined tumor (mRECIST 1.1);\n6. Tumor burden≤50% of the total liver volume;\n7. Child-Pugh score≤7;\n8. Adequate organ function: # Blood routine: absolute neutrophil count ≥ 1.5×10\\^9\u002FL; platelet≥75×10\\^9\u002FL; hemoglobin≥90 g\u002FL; # Liver function: total bilirubin≤2 times upper limit of normal (ULN); alanine transaminase and aspartate aminotransferase≤5.0 ULN; alkaline phosphatase≤2.5 ULN; Albumin\\>30 g\u002FL; # Renal function: Cr≤1.5 ULN; creatinine clearance≥50 mL\u002Fmin; # Coagulation function: international normalized ratio, prothrombin time and activated partial thromboplastin time were less than 1.5 ULN;\n9. Women and men of childbearing age must agree to take strict and effective contraceptive measures during the study period and within 6 m after the end of the trial.\n\nExclusion Criteria:\n\n1. With previous history of hepatic encephalopathy;\n2. Extrahepatic disease or combined with other malignant tumors;\n3. Infiltrative hepatocellular carcinoma ;\n4. With prior antitumor therapies, including liver transplantation, hepatectomy, ablation, TACE, chemotherapy, radiotherapy, targeted therapy or immunotherapy;\n5. With hepatic artery malformation and unable to undergo TACE or SIRT;\n6. Allergy to contrast agents or anesthetics\n7. With clinical manifestations of portal hypertension, moderate-severe or refractory ascites, or decompensated liver cirrhosis, or moderate-to-severe esophageal\u002Fgastric varices;\n8. With severe pulmonary insufficiency (forced expiratory volume at one second \u002F forced vital capacity\\\u003C50% or forced expiratory volume at one second \u002Fpredicting value\\\u003C50% or maximum volume per minute\\\u003C50 L\u002Fmin);\n9. The single lung radiation absorbed dose\\>30 Gy;\n10. Tumor thrombus in main portal vein or hepatic artery or hepatic vein or bile duct;\n11. Serious infections in active stage or need systematic treatment;\n12. Pregnant and lactating women;\n13. With positive results of HIV antibody test;\n14. HBV DNA or HCV RNA positive;\n15. With active syphilis or tuberculosis;\n16. 99mTc-MAA imaging (patients exclusion meet all criteria):\n\n1\\) Perfusion area covers all intrahepatic tumors (including non-target lesions) and non-perfused liver volume ≥30% of total liver volume; 2) Tumor dose ≥400 Gy for 1-2 hepatic segments; Perfused normal liver dose (PNLD): 120 Gy \\\u003C PNLD \\\u003C1000 Gy; Tumor dose ≥200 Gy (recommended ≥400 Gy) and PNLD \\\u003C120 Gy with other condition; 3) No gastrointestinal shunt , or shunt amendment by endovascular techniques (reassessment required); 4) cTACE should cover all intrahepatic lesions.",{"count":385,"type":22},108,[149],"To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma",[389],"Unresectable Hepatocellular Carcinoma",[391,392,393,394],"HCC","TACE","Selective internal radiation therapy","Yttrium-90","2025-04-06",{"date":397,"type":32},"2025-04-09",{"date":399,"type":32},"2025-04-03",{"date":401,"type":22},"2027-01-30",{"name":38,"class":39},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":193,"enrollmentInfo":411,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":430},"100583471","regional-lymph-node-metastasis-and-survival-outcomes-in-advanced-hcc-100583471","NCT06876753","Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC","Regional Lymph Node Metastasis and Survival Outcomes in Advanced Hepatocellular Carcinoma Receiving Transarterial Chemoembolization and PD-(L)1 Inhibitors-based Immunotherapy","CHANCE2421","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of extrahepatic spread;\n3. Has not received any previous systemic therapy for HCC (including chemotherapy, molecularly targeted therapy, immunotherapy);\n4. Both PD-1\u002FPD-L1 inhibitors and anti-angiogenesis drugs patients received only include marketed drugs but are not limited to HCC approval;\n5. TACE was performed after the first PD-1\u002FPD-L1 inhibitor\u002Fanti-angiogenic drug treatment or before treatment (within 3 months);\n6. Received at least 1 cycle of PD-1\u002FPD-L1 inhibitor\u002Fanti-angiogenic drug combination therapy after TACE treatment;\n7. Has repeated measurable intrahepatic lesions;\n\nExclusion Criteria:\n\n1. Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular\u002Fcholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible;\n2. Unable to meet criteria of combination timeframe described above;\n3. Child-Pugh C or PS \\> 2 or Severe hepatic encephalopathy",{"count":412,"type":22},300,"Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based efficacy is unclear. This study aimed to evaluate whether extrahepatic LNM is associated with worse survival outcomes as compared to other metastatic sites in patients with advanced HCC.",[415],"Hepatocellular Carcinoma (HCC)",[417,418,419,420,421],"hepatocellular carcinoma","lymph node metastasis","transarterial chemoembolization","immune checkpoint inhibitors","molecular target therapies","2025-03-10",{"date":424,"type":32},"2025-03-14",{"date":426,"type":32},"2018-06-01",{"date":428,"type":22},"2025-07-01",{"name":38,"class":39},2,{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":440,"conditions":441,"keywords":445,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":430},"100581352","dynamic-prediction-model-for-patients-with-unresectable-biliary-malignancies-receiving-systemic-chemotherapy-combined-with-immunotherapy-a-multicenter-observational-study-100581352","NCT06849193","Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study","BTCICTY-001","Inclusion Criteria:\n\n* 1\\. Confirmed by histopathological diagnosis and\u002For clinical diagnosis (typical imaging features, clinical manifestations, laboratory examination, etc.) as biliary malignancy (Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Biliary malignancy (2024)); 2. Based on unresectable malignant tumor in the diagnosis of biliary and in patients undergoing chemotherapy with immunosuppressant therapy system; 3. The liver function class for Child - Pugh, A or B; 4. More than 18 years of age, gender not limited; 5. Expected survival time for 3 months or more; 6. ECOG PS score 2 or less; 7. Meet the following laboratory test parameters:\n\n  1. Hematological system function: Absolute neutrophil count ≥ 1.0×10⁹\u002FL; platelet count ≥ 50×10⁹\u002FL; hemoglobin ≥ 90 g\u002FL; international normalized ratio less than 1.7 or prothrombin time prolongation not exceeding 4 seconds.\n  2. Liver function: Alanine aminotransferase\u002Faspartate aminotransferase not exceeding 5 times the upper limit of normal; total bilirubin ≤ 210 μmol\u002FL \\[≤ 2.38 mg\u002FdL\\]; albumin ≥ 28 g\u002FL.\n  3. Renal function: Serum creatinine not exceeding 1.5 times the upper limit of normal.\n\nExclusion Criteria:\n\n* Malignant tumors other than BTC;\n* Moderate to severe ascites (ascites reaching a Child-Pugh score of 3);\n* Any local treatment (including transcatheter interventional therapy, ablation therapy, internal\u002Fexternal radiotherapy, etc.) or surgical resection or traditional Chinese medicine within 4 weeks before the combination of systemic chemotherapy and immunotherapy;\n* Incomplete data, such as incomplete laboratory test data, missing or poor-quality imaging data, or lack of prognostic information;\n* Severe liver dysfunction, such as decompensated cirrhosis and other liver diseases that significantly affect bilirubin levels;\n* Severe comorbidities, such as refractory hypertension (blood pressure still higher than 150\u002F100 mm Hg after optimal drug treatment), persistent arrhythmia (CTCAE grade 2 or above), any degree of atrial fibrillation, prolonged QTc interval (more than 450 milliseconds in men and more than 470 milliseconds in women), renal insufficiency, etc.;\n* Human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome;\n* Pregnant or lactating women;\n* Acute or chronic mental disorders (including mental disorders that affect the subject's enrollment, treatment intervention, and follow-up).",{"count":439,"type":22},332,"This study focused on the longitudinal tumor burden profile (tumor macro features, histopathological types and imaging features, etc.), liver function, health status, tumor biomarkers, and serological indicators of patients with unresectable biliary malignancies before chemotherapy combined with immunotherapy to build a dynamic prediction model. Based on this model, risk stratification of BTC patients was realized to explore which specific populations could safely initiate combination therapy. By constructing a risk stratification model, it can help clinicians to screen the best treatment population and provide a basis for safe treatment of high-risk patients.",[442,443,444],"Unresectable Biliary Tract Cancer","Dynamic Prediction Model","Immunotherapy",[442,446,447,448],"immunotherapy","Dynamic prediction model","systemic chemotherapy","2025-02-23",{"date":451,"type":32},"2025-02-27",{"date":453,"type":32},"2025-01-31",{"date":455,"type":22},"2026-05-31",{"name":38,"class":39},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":466,"conditions":467,"keywords":471,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":40},"100581351","novel-subtypes-and-treatment-strategies-of-patients-with-unresectable-combined-hepatocellular-cholangiocarcinoma-based-on-multimodal-data-100581351","NCT06849180","Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data","Novel Subtypes and Treatment Strategies of Patients with Unresectable Mixed Hepatocellular Cholangiocarcinoma Based on Multimodal Data","Inclusion Criteria:\n\n1. age ≥18 years; diagnosis of CHC confirmed by histology or cytology;\n2. patients with unresectable or metastatic CHC diagnosed on the basis of unresectable CHC who have received prior local therapy, systemic therapy, or a combination of both and have at least one measurable lesion (RECIST v1.1);\n3. survival time ≥ 3 months;\n4. ECOG PS 0-2;\n5. Child-Pugh A\u002FB.\n\nExclusion Criteria:\n\n1. pregnant women, lactating women, and men and women of childbearing age who are unwilling or unable to use effective contraception.\n2. history of other malignant tumors within the past five years, unless these tumors have been completely treated and have been free of active disease for five years prior to the first dose and are at low risk of recurrence.\n3. fully treated carcinoma in situ with no evidence of disease.\n4. history of gastrointestinal bleeding or significant bleeding tendency (e.g., with known active ulcers, fecal occult blood, etc.) within the past six months that precludes inclusion in the study; gastroscopy is required if there is persistent fecal occult blood.\n5. substantial organ transplantation or bone marrow transplantation within two years prior to the first dose, or active autoimmune disease requiring systemic therapy.\n6. other conditions that the investigator deems unsuitable for inclusion in the study. Inadequate information, such as incomplete data from laboratory tests, missing or poor quality imaging data, no prognostic information, etc., that the investigator considers unsuitable for inclusion in the study.",{"count":465,"type":22},198,"This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial intelligence and multi-omics, and exploring the optimal treatment strategies for patients with different subtypes, helping clinicians to screen the most beneficial groups of various treatment schemes, and providing new ideas for safe treatment of high-risk patients.",[468,469,470],"Combined Hepatocellular-cholangiocarcinoma","Combined Hepatocellular Carcinoma and Cholangiocarcinoma","Combined Hepatocellular and Cholangiocarcinoma",[472,473],"CHC","cHCC-ICC",{"date":451,"type":32},{"date":476,"type":32},"2024-12-31",{"date":478,"type":22},"2026-02-28",{"name":38,"class":39},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":486,"maxAge":48,"enrollmentInfo":487,"targetDuration":4,"studyType":99,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":40},"100569468","intravascular-radiofrequency-ablation-of-sympathetic-nerves-for-the-treatment-of-hepatocellular-carcinoma-100569468","NCT06694636","Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Clinically or pathologically confirmed hepatocellular carcinoma (HCC)\n* Locally progressed or distant metastatic unresectable advanced HCC\n* Progressed after second-line therapy\n* Agree to participate in the study and sign the informed consent form\n\nExclusion Criteria:\n\n* Not suitable for ablation surgery\n* Pregnant, lactating and planning to become pregnant\n* Orthostatic hypotension\n* Mixed liver cancer\n* Intestinal obstruction\n* Obvious bleeding tendencies and hematologic diseases\n* Acute or severe systemic infection;\n* Stroke or transient ischemic attack (TIA) within two weeks;\n* Acute coronary syndrome within two weeks;\n* Evaluated to be not suitable for this trial by investigators","25 Years",{"count":488,"type":22},5,[149],"Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT\u002Fmagnetic resonance, etc.",[492],"Hepatocellular Carcinoma",[492,494,495],"Sympathetic Nerves","Intravascular Radiofrequency Ablation","2024-11-18",{"date":498,"type":32},"2024-11-19",{"date":500,"type":32},"2024-02-01",{"date":34,"type":22},{"name":38,"class":39},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":40},"100567529","tace-combined-with-icis-plus-mtt-after-125i-irradiation-stent-placement-in-hcc-with-main-pvtt-100567529","NCT06669377","TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.","Transcatheter Arterial Chemoembolization Combined With ICIs Plus MTT After Irradiation Stent Placement in HCC With Main PVTT: a Multicenter Propensity Score Matching Study","Inclusion Criteria:\n\n1. age ≥18 years old; (2) diagnosis of HCC is confirmed through histological or cytological analysis, as well as clinical features; (3) histologically confirmed or imaging-diagnosed PVTT extending to the main portal vein (Vp4); (4) including at least one measurable intrahepatic lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; (5) Eastern Cooperative Oncology Group (ECOG) performance status of ≤2; (6) patients received first-line treatment with either ICIs-MTT or an ISP-containing quadruple combination within eight weeks (In the ICIs-MTT group, MTT was administered alongside ICIs. In the ISP-containing quadruple, TIT and ICIs-MTT were given after stent placement and portal vein recanalization, either simultaneously or within eight weeks before or after the ICIs-MTT therapy).\n\nExclusion Criteria:\n\n1. patients with extrahepatic metastases; (2) a history of or concurrent malignancies; (3) patients underwent prior systemic treatments or locoregional therapies, including surgery, radiation therapy, hepatic arterial embolization, TACE, hepatic arterial infusion, radiofrequency ablation, percutaneous ethanol injection, and cryoablation, within three months before the initiation of ISP.; (4) Child-Pugh grade C liver function, a Child-Pugh score of 3 for ascites, or the presence of overt hepatic encephalopathy; (5) incomplete outcome data or missing essential baseline factors for analysis.",{"count":511,"type":22},444,"Hepatocellular carcinoma (HCC) patients with Vp4 \\[main trunk\\] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits. We aimed to assess the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with immune checkpoint inhibitors (ICIs) plus molecular targeted therapy (MTT) after irradiation stent placement (ISP) as first line treatment for HCC patients with Vp4 PVTT.",[492],[417,515,516,517,518,519],"irradiation stent","portal vein tumor thrombosis","immune checkpoint inhibitor","molecular targeted therapy","transcatheter arterial chemoembolization","2024-10-31",{"date":522,"type":32},"2024-11-01",{"date":524,"type":32},"2024-01-01",{"date":526,"type":22},"2025-03-31",{"name":38,"class":39},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":537,"conditions":538,"keywords":539,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":40},"100562742","prognosis-stratification-for-advanced-hcc-receiving-tace-with-pd-1pd-l1-inhibitors-and-molecular-target-therapies-100562742","NCT06607120","Prognosis Stratification for Advanced HCC Receiving TACE with PD-1\u002FPD-L1 Inhibitors and Molecular Target Therapies","Personalized Model of Prognosis Stratification for Patients with Advanced HCC Receiving TACE Combined with PD-1\u002FPD-L1 Inhibitors Plus Molecular Target Therapies","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of extrahepatic spread and\u002For macrovascular invasion;\n3. Has not received any previous systemic therapy for HCC (including chemotherapy, molecularly targeted therapy, immunotherapy);\n4. Both PD-1\u002FPD-L1 inhibitors and anti-angiogenesis drugs patients received only include marketed drugs but are not limited to HCC approval;\n5. TACE was performed after the first PD-1\u002FPD-L1 inhibitor\u002Fanti-angiogenic drug treatment or before treatment (within 3 months);\n6. Received at least 1 cycle of PD-1\u002FPD-L1 inhibitor\u002Fanti-angiogenic drug combination therapy after TACE treatment;\n7. Has repeated measurable intrahepatic lesions;\n\nExclusion Criteria:\n\n1. Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular\u002Fcholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible;\n2. Unable to meet criteria of combination timeframe described above;\n3. Child-Pugh C or PS\\>2 or Severe hepatic encephalopathy",{"count":536,"type":22},950,"The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies.",[492],[417,419,420,421,540,541],"advanced stage","prognosis model","2024-09-20",{"date":544,"type":32},"2024-09-23",{"date":546,"type":32},"2024-06-01",{"date":548,"type":22},"2025-03-01",{"name":38,"class":39},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":193,"enrollmentInfo":557,"targetDuration":4,"studyType":99,"phases":559,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":40},"100561730","tace-with-thermosensitive-nanogel-versus-embosphere-for-hcc-100561730","NCT06593964","TACE With Thermosensitive Nanogel Versus Embosphere for HCC","Safety and Efficacy of TACE With Thermosensitive Nanogel Embolic Agent Versus Embosphere for Hepatocellular Carcinoma: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Trial","Inclusion Criteria:\n\n1. Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection, transplantation, or ablation;\n2. Liver function status: Child-Pugh A or B\n3. Eastern Cooperative Oncology Group score: 0-2 points;\n4. With at least one measurable, unembolized liver tumor lesion (1-10 cm) ;\n5. Willing to participate in this trial and sign the informed consent.\n\nExclusion Criteria:\n\n1. The target lesion has been embolized before or require combined with other treatment(s);\n2. Diffuse or with extrahepatic metastasis;\n3. Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds);\n4. Severe renal dysfunctions (creatinine clearance rate \\\u003C30 ml\u002Fmin);\n5. Severe liver dysfunctions (alanine aminotransferase or aspartate aminotransferase exceeding the upper limit of normal by 5 times);\n6. Main portal vein was completely occluded and no collateral blood supply was established;\n7. With uncorrectable arteriovenous fistula or portal vein fistula;\n8. Severe cachexia or hepatic encephalopathy;\n9. With active infection;\n10. Significant reductions in white blood cells or platelets (white blood cells\\\u003C3.0x109\u002FL, platelets\\\u003C50x109\u002FL) that cannot be corrected;\n11. Pregnant or lactating women;\n12. Difficulty in selective catheterization;\n13. With the severe risk of non-target embolization;\n14. Severely allergic to contrast agents or the embolic materials;\n15. Participating in ongoing trial;\n16. Unsuitable judged by the investigator.",{"count":558,"type":22},188,[149],"To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.",[389],[563,564],"Hepatocellular carcinoma","Transarterial Chemoembolization","2024-09-09",{"date":567,"type":32},"2024-09-19",{"date":569,"type":22},"2024-09-10",{"date":571,"type":22},"2026-04-30",{"name":38,"class":39},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":579,"minAge":4,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":593,"locationsCount":40},"100551305","identification-of-risk-factors-and-construction-of-prediction-model-for-postoperative-intestinal-anastomotic-leakage-in-ovarian-cancer-100551305","NCT06458361","Identification of Risk Factors and Construction of Prediction Model for Postoperative Intestinal Anastomotic Leakage in Ovarian Cancer","Inclusion Criteria:\n\n1. Patients with postoperative pathological diagnosis of primary ovarian, fallopian tube or peritoneal cancer\n2. Patients undergoing tumour cytoreductive surgery combined with colorectal resection and stage I intestinal anastomosis\n3. No history of other malignant tumours\n4. Complete case data\n\nExclusion Criteria:\n\n1. Previous combination of malignant tumours of other organs\n2. Comorbidities with serious diseases related to other organs\n3. Patients undergoing secondary tumour cytoreduction","FEMALE",{"count":412,"type":22},"This study was a multicenter, retrospective cohort study. Although advancements in surgical techniques have mitigated the incidence of intestinal anastomotic fistula, complete avoidance remains elusive. Anastomotic leakage (AL) complications directly impinge on postoperative quality of life and pose life-threatening risks if inadequately managed. Given AL's adverse prognostic implications and the financial strain on patients' families, identifying its risk factors aids in perioperative risk assessment, enabling timely clinical decisions on interventions to enhance prognosis and curtail adverse outcomes and economic investments.",[583],"Ovarian Cancer",[585,586,583],"Anastomotic Leakages","Risk Factors","2024-06-09",{"date":589,"type":32},"2024-06-13",{"date":591,"type":32},"2018-01-01",{"date":522,"type":22},{"name":38,"class":39},""]